Petrova Stella P, Gao Chengzhe, Hiew Tze Ning, Edgar Kevin J, Taylor Lynne S
Department of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA; Department of Chemistry, College of Science, Virginia Tech, Blacksburg, VA, 24061, USA; Macromolecules Innovation Institute, Virginia Tech, Blacksburg, VA, 24061, USA.
Department of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
J Pharm Sci. 2025 Jan;114(1):544-553. doi: 10.1016/j.xphs.2024.10.034. Epub 2024 Oct 30.
Polymeric additives are widely used to delay drug crystallization from supersaturated solutions, which is critical for enhancing oral bioavailability by amorphous solid dispersion (ASD). The efficacy of these polymers relies on their capacity to inhibit nucleation and subsequent crystal growth. Drug nucleation is pivotal to crystallization; therefore, effective polymers are essential for suppressing nucleation from supersaturated solutions. We studied the performance of cellulose ω-carboxyalkanoates designed as crystallization inhibitors by measuring their influence on nucleation induction times of poorly soluble drugs celecoxib, posaconazole, and enzalutamide, from supersaturated solutions. In the absence of polymers, crystallization occurred within 5 to 15 minutes for all three drugs. Polymer hydrophobicity strongly influenced effectiveness in crystallization inhibition. Hydrophobic polymers prolonged induction times for up to 8 hours, while hydrophilic polymers were less effective, except for cellulose acetate glutarate (CA-GA; degrees of substitution acetate 1.18, glutarate 1.21). The cellulose ω-carboxyalkanoates had glass transition temperatures well above 100 °C, outstanding for ASD stability requirements. We investigated the impact of these designed polymers on surface tension and found that it only weakly influenced crystallization inhibition. Among the nine crafted cellulose derivatives, water-soluble CA-GA emerged as a highly promising ASD polymer, preventing crystallization for 2-8 hours for all fast-crystallizing model compounds.
聚合物添加剂被广泛用于延缓药物从过饱和溶液中结晶,这对于通过无定形固体分散体(ASD)提高口服生物利用度至关重要。这些聚合物的功效取决于它们抑制成核和后续晶体生长的能力。药物成核是结晶的关键;因此,有效的聚合物对于抑制过饱和溶液中的成核至关重要。我们通过测量它们对难溶性药物塞来昔布、泊沙康唑和恩杂鲁胺从过饱和溶液中成核诱导时间的影响,研究了设计为结晶抑制剂的ω-羧基链烷酸纤维素的性能。在没有聚合物的情况下,所有三种药物在5至15分钟内发生结晶。聚合物疏水性对结晶抑制效果有很大影响。疏水性聚合物将诱导时间延长至8小时,而亲水性聚合物效果较差,除了醋酸-戊二酸纤维素(CA-GA;醋酸取代度1.18,戊二酸取代度1.21)。ω-羧基链烷酸纤维素的玻璃化转变温度远高于100°C,对于ASD稳定性要求来说非常出色。我们研究了这些设计的聚合物对表面张力的影响,发现它对结晶抑制的影响很小。在九种精心制备的纤维素衍生物中,水溶性CA-GA成为一种非常有前途的ASD聚合物,对所有快速结晶的模型化合物都能防止结晶2-8小时。